U-M Division of GI & Hepatology Researchers

The innovative research conducted by our physicians and faculty has paved the way for more effective methods of prevention, diagnosis, and treatment of gastrointestinal diseases.

Dr. Robert Fontana discusses his study that has global impact on Hepatitis C elimination efforts.

In our mission to create knowledge through research, the Division of Gastroenterology and Hepatology continues to conduct cutting-edge investigations of the molecular, cellular, and physiological conditions of healthy and diseased states of the gastrointestinal tract, liver, and pancreas. The central piece of the Division's research endeavor is the NIH-funded University of Michigan Center for Gastrointestinal Research, which encompasses three thematic areas of research:

  1. neurobiology of appetite control and visceral pain
  2. molecular and cellular mechanisms of inflammation
  3. cell growth, differentiation, and programmed cell death

Research Highlights

Existing Drugs Kill SARS-CoV-2 in Cells

Jonathan Sexton, PhD and team discover several drug contenders already in use for other purposes that have been shown to block or reduce SARS-CoV-2 infection in cells.

Tofacitinib for Severe Ulcerative Colitis: Will It Prevent Colectomies?

Jeffrey Berinstein, MD; Peter Higgins, MD, PhD; and team explore the benefits of tofacitinib when treating patients with acute severe ulcerative colitis.

A Better Approach to Caring for Cirrhosis

Elliot Tapper, MD and Neehar Parikh, MD, MS evaluate the existing gaps in care for individuals with cirrhosis and discuss how to improve the quality of life for these patients, as well as implementing effective preventative measures.

What Are the Effects of Terlipressin When Treating HRS-1?

Pratima Sharma, MBBS, MD, MS discusses her clinical trial that looked into the efficacy and safety of terlipressin plus albumin in adults with type 1 hepatorenal syndrome (HRS-1).